Actylis, a provider of choice for life sciences and advanced technology specialty ingredients, today announced the strategic acquisition of Pharm-Rx, a leading value-added supplier of specialty ingredients for the vitamin, mineral, and supplement (“VMS”) and pharmaceutical industries. The Pharm-Rx acquisition significantly enhances Actylis’ ability to deliver exceptional value to its customers, increases its range of solutions for clients, and strengthens its strategic supplier partnerships to enhance its innovative portfolio and service offerings. Pharm-Rx’s strong team and industry expertise broadens Actylis’ capabilities to help accelerate growth with nutrition and over-the-counter (OTC) pharmaceutical customers. Additionally, current President & Head of Business Development for Pharm-Rx, Mark Bostel, will be assuming the role of President, Global Nutrition and OTC for Actylis, leading both Pharm-Rx and Actylis’ Nutrition and OTC businesses.
For more than 30 years, Saddle Brook, NJ-based Pharm-Rx has been a leading supplier of active ingredients to the VMS, OTC, and prescription pharmaceutical markets. The company is well known for its customer-centric approach, providing difficult-to-find specialty ingredients from premier manufacturers globally. Pharm-Rx has developed industry-leading expertise in addressing customer needs, overcoming regulatory hurdles, and navigating international logistics complexities.
Scott Thomson, Actylis CEO, said, “We are thrilled to welcome Pharm-Rx into the Actylis family. This acquisition is a significant milestone in our growth strategy, allowing us to offer even greater value to our customers through an expanded portfolio and enhanced capabilities and expertise. By leveraging our combined strengths, we are poised to deliver the most innovative solutions to meet the ever-evolving needs of the markets that we serve. We are excited to welcome Mark Bostel to the Actylis leadership team and work together to drive accelerated growth for our combined nutrition and OTC business in partnership with our customers.”
Mark Bostel added, “Pharm-Rx found the ideal partner in Actylis – their strengths perfectly align with ours. It is clear that together, we can offer our suppliers broader access to clients globally while expanding our differentiated product offerings to our loyal and growing customer base. We are most excited about the complementary nature of our businesses, positioning us to better serve our markets and unlock new opportunities.”
Pharm-Rx will continue to operate under its current brand within Actylis and be led by the current management team including Mark Bostel, Carlos Doussinague, and Ann Smith.
Alantra and Adams and Reese LLP advised Pharm-Rx on the transaction. UB Greensfelder LLP advised Actylis. Financial terms of the transaction were not disclosed.
